Advanced prostate cancer—a case for adjuvant differentiation therapy

  title={Advanced prostate cancer—a case for adjuvant differentiation therapy},
  author={Jayant K. Rane and Davide Pellacani and Norman J. Maitland},
  journal={Nature Reviews Urology},
The development of novel therapies such as abiraterone acetate and sipuleucel-T has improved the outlook for patients with advanced-stage and castration-resistant prostate cancer. However, the beneficial effects of these drugs are only measured in months. Moreover, the National Institute for Health and Clinical Excellence in the UK had ruled that the use of abiraterone acetate was not cost-effective before cost revision by the manufacturers. The FDA statement asserting that the use of 5… 

Targeting the Prostate Stem Cell for Chemoprevention

This chapter will discuss the use of chemoprevention to target cancer stem cells and how these approaches can be applied to prostate cancer.

Molecular pathways and targets in prostate cancer

This review summarizes the current understanding of the molecular pathways involved in localized and metastatic prostate cancer, with an emphasis on the clinical implications of the new knowledge.

Cancer Stem Cells Provide New Insights into the Therapeutic Responses of Human Prostate Cancer

The role of cancer stem cells in tumour relapse as well as the potential they provide to develop novel treatment strategies are described and three strategies to target both cancer stem Cells and bulk tumour cells are proposed.

Reversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and review of the literature

The case of a 73-year-old man, affected by bone metastatic CRPC, early treated with Radium-223 with a complete response and to the knowledge, he is the unique described case of the reversion of resistance to castration.

Loss of SLCO1B3 drives taxane resistance in prostate cancer

The SLCO1B3 determines intracellular concentrations of docetaxel and cabazitaxe and consequently influences taxane efficacy and may drive taxane resistance in prostate cancer.

Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer

Major biomarkers for prostate cancer stem cells are summarized, as well as their functional mechanisms and potential application in clinical diagnosis and treatment of patients.

Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review

The cost-effectiveness of treatments of CRPC strongly depended on the willingness to pay per quality-adjusted life year gained/life-year saved throughout all included costs-effectivity analyses and model-based economic evaluations.

The Efflux Transporter ABCG2 Maintains Prostate Stem Cells

Prostate stem cells (PSC) are characterized by their intrinsic resistance to androgen deprivation therapy (ADT), possibly due to the lack of androgen receptor (AR) expression. PSCs resistance to ADT

Models of Tumor Progression in Prostate Cancer

Animal models are needed to investigate and validate molecular mechanisms and to develop therapeutic principles in the pipeline between in vitro experiments and clinical applications, and advances in three-dimensional organoid culture technology represent a breakthrough in prostate cancer research.



The changing therapeutic landscape of castration-resistant prostate cancer

A treatment pathway for patients with CRPC is proposed and strategies to optimize the use of these agents are considered, including the incorporation of predictive and intermediate end point biomarkers, such as circulating tumor cells.

Abiraterone and increased survival in metastatic prostate cancer.

The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.

Abiraterone in Prostate Cancer: A New Angle to an Old Problem

Abiraterone's efficacy shows the importance of androgen signaling in patients with castrate-resistant metastatic disease, with additional confirmation from recent studies of other novel agents such as MDV3100, an androgen receptor signaling inhibitor.

Gamma‐tocotrienol as an effective agent in targeting prostate cancer stem cell‐like population

It is demonstrated for the first time that γ‐T3 can downregulate the expression of prostate CSC markers (CD133/CD44) in androgen‐independent prostate cancer cell lines (PC‐3 and DU145), as evident from Western blotting analysis.

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

  • Y. NingJ. Gulley W. Dahut
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
The addition of bevacizumab and thalidomide to docetaxel is a highly active combination with manageable toxicities, and the estimated median survival is encouraging, given the generally poor prognosis of this patient population.

Prospective identification of tumorigenic prostate cancer stem cells.

The identification and characterization of a cancer stem cell population from human prostate tumors, which possess a significant capacity for self-renewal and are able to regenerate the phenotypically mixed populations of nonclonogenic cells, which express differentiated cell products.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.

The effects of telomerase inhibition on prostate tumor‐initiating cells

It is found that prostate TICs have significant telomerase activity which is inhibited by imetelstat sodium (GRN163L), a new telomersase antagonist that is currently in Phase I/II clinical trials for several hematological and solid tumor malignancies.